CRISPR Therapeutics AG (NASDAQ:CRSP) price on Thursday, Dec 10, rose 5.2% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $154.26.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

A look at the stock’s price movement, the close during the last trading session was $146.63, moving within a range at $140.21 and $156.59. The beta value (5-Year monthly) is 2.34 while the PE ratio in trailing twelve months stood at 0. Turning to its 52-week performance, $163.56 and $32.3 were the 52-week high and 52-week low respectively. Overall, CRSP moved 56.29% over the past month.

CRISPR Therapeutics AG’s market cap currently stands at around $10.38 Billion, with investors looking forward to this quarter’s earnings report slated for Feb 10, 2021- Feb 15, 2021. The company has a Forward Dividend ratio of 0, with its dividend yield at 0%. As such, investors might be keen on a downside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be -$1.27, which has seen fiscal year 2020 EPS growth forecast to decrease to -$5.02 and about -$5.31 for fiscal year 2021. Per the data, EPS growth is expected to be -5.29% for 2020 and 0.06% for the next financial year.

Turning to the stock’s technical picture we see that short term indicators suggest on average that CRSP is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.

19 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 7 analyst(s) rate the stock as a Hold, 10 recommend CRSP as a Buy and none give it an Outperform rating. Meanwhile, none analyst(s) rate the stock as Underperform and 2 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

The technical evaluation for the stock shows the PEG ratio is 0, with CRSP’s current price about 27.6% and 46.05% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 81.93, while 7-day volatility ratio is 1063% and 6.34% in the 30-day chart. Further, CRISPR Therapeutics AG (CRSP) has a beta value of 2.34, and an average true range (ATR) of 9.29. Analysts have given the company’s stock an average 52-week price target of $137.63, forecast between a low of $45 and high of $180. Looking at the price targets, the low is -70.83% off current price level while to achieve the yearly target high price needs to move +16.69%. Nonetheless, investors will most likely welcome a -0.82% jump to $153 that is the analysts’ median price.

In the market, a comparison of CRISPR Therapeutics AG (CRSP) and its peers suggest the former has performed considerably better. Data shows CRSP’s intraday price has changed +5.2% today and +134.97% over the past year. Comparatively, Bristol-Myers Squibb Company (BMY) has moved -1.18% on the day and only -3.54% in the past 12 months. Looking at another peer, we see that Amgen Inc (AMGN) price has dipped -0.74% on the day. However, the stock is -2.5% off its price today a year ago. Moreover, Gilead Sciences Inc (GILD) is also up 5.2% in today trading while keeping an uptrend of 134.97% over the past year. If we look at the PE ratio, we find that CRISPR Therapeutics AG’s ratio stands at 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 18.4. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.13% and down -0.23% respectively on the day as seen in early trades.

If we refocus on CRISPR Therapeutics AG (NASDAQ:CRSP), historical trading data shows that trading volumes averaged 2.05 Million over the past 10 days and 1.08 Million over the past 3 months. The company’s latest data on shares outstanding shows there are 70.65 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

As per Thomson Reuters, 13.8% of CRISPR Therapeutics AG’s shares are in the hands of company insiders while institutional holders own 69.3% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.31 Million on November 29, 2020, giving us a short ratio of 5.31. The data shows that as of November 29, 2020 short interest in CRISPR Therapeutics AG (CRSP) stood at 6.09% of shares outstanding, with shares short dropping from 6.33 Million registered in October. Current price change has pushed the stock +153.28% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CRSP stock continues to rise going into the next quarter.


The small cap to buy before 2021

There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune!

Get all the details here >>

Sponsored




Source link